The Global Health Body Sounds Alert Over Acute Lack of Obesity Jabs

Fewer than a tenth of people eligible to benefit from GLP-1 drugs such as Wegovy can access them, states the global health agency as it releases its first advice on the therapies.

With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for broader and more equitable availability to this class of drugs.

Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.

"The new guidance recognises that obesity is a chronic disease that can be managed with comprehensive and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are key obstacles to broad access to the jabs that can aid individuals in losing considerable weight, notes the organization.

Weight-Loss Drug Scarcity

Even under the present best projected outlook, the manufacturing of such drugs might only reach about 100 million people – fewer than 10% of those who need them, according to the health organization.

The recommendation encourages nations and manufacturers to widen access, by strategies such as licensing agreements.

The intellectual property rights on semaglutide – the main component of a leading brand – is scheduled to end in several nations in 2026.

The Way Weight-Loss Injections Function

The injections mimick a natural hormone to reduce digestion speed, curb appetite and boost the sense of being full so users eat less.

Individuals usually begin shedding pounds within a few weeks of commencing the weekly injections.

Evidence points to patients may put most of the weight back on a year later of stopping the treatment, as their normal food cravings resume.

Being overweight or obese raises your risk for experiencing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers.

Excess weight impacts individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.